Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32

Journal of Allergy and Clinical Immunology

Volumn 142, Issue 2, 2018, Pages 497-509.e9

  Niederberger, Verena ^a   Neubauer, Angela ^b   Gevaert, Philippe ^c   Zidarn, Mihaela ^d   Worm, Margitta ^e   Aberer, Werner ^f   Malling, Hans Jørgen ^g   Pfaar, Oliver ^h,i   Klimek, Ludger ^h   Pfützner, Wolfgang ^j   Ring, Johannes ^k   Darsow, Ulf ^k   Novak, Natalija ^l   Gerth van Wijk, Roy ^m   Eckl Dorna, Julia ^a   Focke Tejkl, Margarete ^a   Weber, Milena ^a   Müller, Hans Helge ⁿ   Klinger, Joachim ^o   Stolz, Frank ^b   Breit, Nora ^b   Henning, Rainer ^b   Valenta, Rudolf ^a,p   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BIOMAY AG   (Austria)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h Center for Rhinology and Allergology   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY HOSPITAL MARBURG   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY OF BONN   (Germany)

^m ERASMUS MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o SynteractHCR Deutschland GmbH   (Germany)

^p INSTITUTE OF IMMUNOLOGY   (Russian Federation)

more..

Author keywords

allergen; allergen immunotherapy; Allergy; B cell epitope based immunotherapy; clinical trial; efficacy; grass pollen allergy; hypoallergenic; recombinant allergen; safety

Indexed keywords

BM 32; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PLACEBO; ALLERGEN; EPITOPE; HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR; VACCINE;

ADULT; ARTICLE; ASTHMA; AUTUMN; B LYMPHOCYTE; CONTROLLED STUDY; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POLLEN ALLERGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOCONJUNCTIVITIS; VACCINATION; VISUAL ANALOG SCALE; ADOLESCENT; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MIDDLE AGED; PLACEBO EFFECT; POACEAE; POLLEN; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; EPITOPES, B-LYMPHOCYTE; FEMALE; HEPATITIS B SURFACE ANTIGENS; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; POACEAE; POLLEN; PROTEIN PRECURSORS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; VACCINATION; VACCINES; YOUNG ADULT;

EID: 85041122135     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2017.09.052     Document Type: Article

References (40)

1. Durham, S.R., Walker, S.M., Varga, E.M., Jacobson, M.R., O'Brien, F., Noble, W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999), 468–475.
2. Larché M., Akdis, C.A., Valenta, R., Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 (2006), 761–771.
3. Jacobsen, L., Niggemann, B., Dreborg, S., Ferdousi, H.A., Halken, S., Høst, A., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62 (2007), 943–948.
4. Bousquet, J., Lockey, R., Malling, H.J., Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102 (1998), 558–562.
5. Jutel, M., Agache, I., Bonnini, S., Burks, A.W., Calderon, M., Canonica, W., et al. International Consensus on Allergen Immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol 137 (2016), 356–368.
6. Cox, L., Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck Surg 23 (2015), 247–254.
7. Valenta, R., Campana, R., Focke-Tejkl, M., Niederberger, V., Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol 137 (2016), 351–357.
8. Focke-Tejkl, M., Weber, M., Niespodziana, K., Neubauer, A., Huber, H., Henning, R., et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol 135 (2015), 1207–1217.
9. Niederberger, V., Marth, K., Eckl-Dorna, J., Focke-Tejkl, M., Weber, M., Hemmer, W., et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol 136 (2015), 1101–1103.
10. Niederberger, V., Horak, F., Vrtala, S., Spitzauer, S., Krauth, M.T., Valent, P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101 (2004), 14677–14682.
11. Purohit, A., Niederberger, V., Kronqvist, M., Horak, F., Grönneberg, R., Suck, R., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38 (2008), 1514–1525.
12. Spertini, F., Perrin, Y., Audran, R., Pellaton, C., Boudousquié C., Barbier, N., et al. Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol 134 (2014), 239–240.
13. Spertini, F., DellaCorte, G., Kettner, A., de Blay, F., Jacobsen, L., Jutel, M., et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol 138 (2016), 162–168.
14. Zieglmayer, P., Focke-Tejkl, M., Schmutz, R., Lemell, P., Zieglmayer, R., Weber, M., et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 11 (2016), 43–57.
15. Bousquet, P.J., Combescure, C., Neukirch, F., Klossek, J.M., Méchin, H., Daures, J.P., et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 62 (2007), 367–372.
16. Pfaar, O., Demoly, P., Gerth van Wijk, R., Bonini, S., Bousquet, J., Canonica, G.W., et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 69 (2014), 854–867.
17. Canonica, G.W., Baena-Cagnani, C.E., Bousquet, J., Bousquet, P.J., Lockey, R.F., Malling, H.J., et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62 (2007), 317–324.
18. Juniper, E.F., Thompson, A.K., Ferrie, P.J., Roberts, J.N., Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104 (1999), 364–369.
19. Marcus, R., Peritz, E., Gabriel, K.R., On closed testing procedures with special reference to ordered analysis of variance. Biometrika 63 (1976), 655–660.
20. Pauli, G., Larsen, T.H., Rak, S., Horak, F., Pastorello, E., Valenta, R., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 122 (2008), 951–960.
21. Alvarez-Cuesta, E., Bousquet, J., Canonica, G.W., Durham, S.R., Malling, H.-J., Valovirta, E., Standards for practical allergen-specific immunotherapy. Allergy 61:suppl 82 (2006), 1–20.
22. Cornelius, C., Schöneweis, K., Georgi, F., Weber, M., Niederberger, V., Zieglmayer, P., et al. Immunotherapy with the PreS-based grass pollen allergy vaccine BM32 induces antibody responses protecting against hepatitis B infection. EBioMedicine 11 (2016), 58–67.
23. Vrtala, S., Hirtenlehner, K., Vangelista, L., Pastore, A., Eichler, H.G., Sperr, W.R., et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 99 (1997), 1673–1681.
24. Vrtala, S., Hirtenlehner, K., Susani, M., Akdis, M., Kussebi, F., Akdis, C.A., et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 15 (2001), 2045–2047.
25. Kahlert, H., Suck, R., Weber, B., Nandy, A., Wald, M., Keller, W., et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 145 (2008), 193–206.
26. Pellaton, C., Perrin, Y., Boudousquié C., Barbier, N., Wassenberg, J., Corradin, G., et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy, 3, 2013, 17.
27. Worm, M., Lee, H.H., Kleine-Tebbe, J., Hafner, R.P., Laidler, P., Healey, D., et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 127 (2011), 89–97.
28. Goidl, E.A., Paul, W.E., Siskind, G.W., Benacerraf, B., The effect of antigen dose and time after immunization on the amount and affinity of anti-hapten antibody. J Immunol 100 (1968), 371–375.
29. González-Fernández, A., Milstein, C., Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation. Immunology 93 (1998), 149–153.
30. James, L.K., Shamji, M.H., Walker, S.M., Wilson, D.R., Wachholz, P.A., Francis, J.N., et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 127 (2011), 509–516.
31. Shamji, M.H., Ljørring, C., Francis, J.N., Calderon, M.A., Larché M., Kimber, I., et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 67 (2012), 217–226.
32. Durham, S.R., Yang, W.H., Pedersen, M.R., Johansen, N., Rak, S., Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006), 802–809.
33. Marth, K., Breyer, I., Focke-Tejkl, M., Blatt, K., Shamji, M.H., Layhadi, J., et al. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol 190 (2013), 3068–3078.
34. Constant, S.L., Bottomly, K., Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 15 (1997), 297–322.
35. Mothes, N., Heinzkill, M., Drachenberg, K.J., Sperr, W.R., Krauth, M.T., Majlesi, Y., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 33 (2003), 1198–1208.
36. Creticos, P.S., Schroeder, J.T., Hamilton, R.G., Balcer-Whaley, S.L., Khattignavong, A.P., Lindblad, R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006), 1445–1455.
37. Valenta, R., Campana, R., Marth, K., van Hage, M., Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 272 (2012), 144–157.
38. Kristiansen, M., Dhami, S., Netuveli, G., Halken, S., Muraro, A., Roberts, G., et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol 28 (2017), 18–29.
39. Westman, M., Lupinek, C., Bousquet, J., Andersson, N., Pahr, S., Baar, A., et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J Allergy Clin Immunol 135 (2015), 1199–1206.
40. Gerlich, W.H., Glebe, D., Development of an allergy immunotherapy leads to a new type of hepatitis B vaccine. EBioMedicine 11 (2016), 5–6.